Send Message
View as an RSS Feed
  • Biolase: Why Your Dentist Is Short This Stock  [View article]
    Interesting presentation. Can you explain what you mean by, "Lasers are dead?" Do you mean dentists are having problems/complications using them in their practice? Or that dentists don't like using them? I'm really interested in what you mean. I can't find anything on the internet regarding this. Please, let me know. Thank you
    May 19, 2015. 06:19 PM | 2 Likes Like |Link to Comment
  • Noodles & Company's Earnings Preview  [View article]
    We love our Noodles! And, we look for a Noodles in every town we travel. You can order on line & it's ready when you go pick it up. Even my son with autism loves eating there. I am a very picky eater & I won't eat at most restaurants but Noodles is one place I will go to. But again, I cannot stand $CMG & the slimy burritos, so there you go.
    Aug 11, 2014. 10:49 AM | Likes Like |Link to Comment
  • Why It Can Be Self-Destructive To Compare Yourself To The S&P 500  [View article]
    Hi Tim! Did you sell BP?
    Jul 29, 2014. 09:09 PM | Likes Like |Link to Comment
  • Evidence grows of links between gum disease and more serious conditions  [View news story]
    This is very old news. There is no doubt that the health of your mouth & teeth have a direct correlation to the body's physiological health! Take care of your teeth & gums because if you have to have dental material, which is full of toxic poisons, put in your mouth/teeth you are doomed! Also, beware of the toxins in "popular" otc meds & in toothpastes/mouthwash!!!
    Aug 7, 2013. 09:49 AM | 1 Like Like |Link to Comment
  • Sequenom Billing Code Drama An Opportunity For Long-Term Investors  [View article]
    Ultrasound Obstet Gynecol. 2013 Jul;42(1):34-40. doi: 10.1002/uog.12504. Epub 2013 Jun 7.
    Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies.
    Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH.

    Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, UK.

    To explore the feasibility of routine maternal blood cell-free (cf) DNA testing in screening for trisomies 21, 18 and 13 at 10 weeks' gestation.
    In this prospective study, women attending The Fetal Medicine Centre in London, UK, between October 2012 and April 2013, with singleton pregnancy and live fetus with CRL 32-45 mm, were screened for trisomies 21, 18 and 13 by cfDNA testing at 10 weeks and the combined test at 12 weeks.
    cfDNA testing was performed in 1005 singleton pregnancies with a median maternal age of 37 (range, 20-49) years. Risks for trisomies were provided for 957 (95.2%) cases and in 98.0% these were available within 14 days from sampling. In 48 (4.8%) cases no result was provided due to problems with delivery to the laboratory, low fetal fraction or assay failure. Repeat sampling was performed in 40 cases and a result obtained in 27 (67.5%) of these. In 11 cases the risk score for trisomy 21 and in five cases that for trisomy 18 was > 99%, in one the risk for trisomy 13 was 34% and in 968 the risk for each of the three trisomies was < 0.01%. The suspected trisomies were confirmed by karyotyping after chorionic villus sampling (CVS), except in one case of trisomy 18 in which the karyotype was normal. On the basis of the maternal age distribution of the study population, the expected and observed numbers for each of the three trisomies were similar. Both cfDNA and combined testing detected all trisomies, but the estimated false-positive rates (FPR) were 0.1% and 3.4%, respectively.
    Routine screening for trisomies 21, 18 and 13 by cfDNA testing at 10 weeks is feasible and has a lower FPR than does combined testing, but abnormal results require confirmation by CVS. Copyright © 2013 ISUOG. Published by John Wiley & Sons Ltd.
    Copyright © 2013 ISUOG. Published by John Wiley & Sons, Ltd

    This article is the first to confirm that this technology will replace all screening methods currently used to detect aneuploidy (trisomies) in low risk populations. As a clinician, I see this new technology will become standard of care. It is less expensive, and has a lower false positive rate than current screening methods.
    Jul 31, 2013. 09:46 PM | Likes Like |Link to Comment
  • Seeking Alpha fires a shot at Bloomberg, StreetAccount  [View news story]
    where are all your earnings reports??? having to resort to schwab's poor newsfeed for this! One of the best about SA was the earnings reports. Will miss it!
    Jul 29, 2013. 09:39 AM | 1 Like Like |Link to Comment
  • Seeking Alpha fires a shot at Bloomberg, StreetAccount  [View news story]
    old format much easier/faster/user friendly. Do appreciate the newsfeed & automatic refresh
    Jul 29, 2013. 07:57 AM | 5 Likes Like |Link to Comment
  • Better late than never: William Blair, Lazard, and Ladenburg Thalmann all downgrade shares of Sequenom (SQNM) on the heels of Wednesday's Q2 report. The stock is now off 36% premarket. (Previous: Payment concerns tank SQNM; Q2 results[View news story]
    Wedbush today maintained an Outperform rating on Sequenom (NASDAQ: SQNM) with a price target of $5.00. Shares tumbled as a result of disappointing earnings on Wednesday. Along with many other companies in the diagnostics industry, Sequenom experienced delays in receipt of payments as a result of molecular diagnostics coding changes adopted by CMS, Medicaid and third party payors. In the view of analyst Zarak Khurshid, issues are not the "end of the world."
    "The new codes appear to be delaying multiple customers by requesting additional information to process claims and many Medicaid plans have yet to implement the new codes, which is also affecting payment from some of the few paying Medicaid states. The company had expected some impact, but was surprised by the magnitude of the effect in 2Q13," said Khurshid.
    He thinks Sequenom will eventually recoup delayed payments.
    "The company says it has already begun to see an improvement with the coding issue in July, which is encouraging . . . We are aggressive buyers below $4," he concluded.
    (from StreetInsider 9:43am)
    Jul 25, 2013. 09:51 AM | Likes Like |Link to Comment
  • Here's a quixotic twist: It appears that battling certain types cancer may lower the risk for developing Alzheimer's disease, new research suggests. After pouring over data, investigators have concluded that most kinds of cancer - with the exception of prostate cancer - seem to confer some degree of protection against Alzheimer's, reducing risk of the age-related brain disorder by anywhere from 9% to 51%. They've also linked a common form of cancer treatment, chemotherapy, to a lower risk for developing Alzheimer's-related dementia.  [View news story]
    I read the study. It does not cover what foods/drinks the patients STOP eating once they are diagnosed/treated for cancer. Additionally, the cancers that were in the study, e.g., pancreatic, have very low survival rates. So even though patients were followed for "six years," & patients were 65 years when study began, further studies should include following patients for at least 20 years & see how many of them are still alive to even be diagnosed with Alzheimers, or any other disease. Chemo drugs are poison, plain & simple, that's why they destroy the cancer, at least temporarily.
    Jul 15, 2013. 01:33 PM | 1 Like Like |Link to Comment
  • Today's Market: There Are Potholes In This Market, But Tons Of Opportunity  [View article]
    As to "lawsuits," check the results. Thus far, ISRG has been the winner. The "fault" has been the individual surgeon's.
    Jul 10, 2013. 10:16 AM | Likes Like |Link to Comment
  • 3 Places To Find A 'Forever Dividend Investment'  [View article]
    "I cannot wait for the price to be right for me to establish a permanent position in Aqua America"
    At what price would you buy WTR? How do you decide on the price (i.e,. depending on the yield at the time...etc., per "Intelligent Investor" rules...)?
    I read all your articles & have learned so much from you-
    Thank you, Tim, for all the time it does take you to write the articles!
    Apr 24, 2013. 04:20 PM | Likes Like |Link to Comment
  • GE (GE +1.7%) says its healthcare unit GE Healthcare announces a research collaboration agreement with Eisai (ESALY.PK, in which the Japanese pharmacuetical developer will use GEs investigational PET amyloid imaging agent to help select patients for a Phase I clinical Alzhiemers trial. The trial evaluates Eisai's investigational compound E2609, a BACE inhibitor designed to prevent the accumulation of beta amyloid in the brain, which is believed to play a role in the in the development of the disease.  [View news story]
    Meanwhile, GE Healthcare Giraffe Incubator and Giraffe OmniBed gets a FDA Class 1 RECALL--"All newborn babies using this device are at risk of serious adverse health consequences, including death, due to this malfunction. Inaccurate temperature can result in hypothermia (dangerously low body temperature) or hyperthermia (dangerously high body temperature), and inaccurate oxygen regulation can result in hypoxia (low blood oxygen) or hyperoxia (high blood oxygen). In addition, newborn babies requiring transport may be at increased risk of adverse health consequences due to potential malfunction when moving from one power source to another (wall outlet to/from battery power)."
    Apr 24, 2013. 02:36 PM | Likes Like |Link to Comment
  • Intuitive Surgical: The Perfect Time To Buy - A Doctor's Perspective  [View article]
    http://bit.ly/Z9AVyt Invasive Surgeons Group Responds to ACOG President's View on Robotic Surgery
    Mar 18, 2013. 02:24 PM | 1 Like Like |Link to Comment
  • Life Technologies (LIFE) -6.8% following a report that the chances of the company being sold have fallen. One of Life's prospective suitors, Thermo Fisher (TMO), is -2.9%[View news story]
    "With Life's recent Street success, Credit Suisse figures any viable buyout offer will have to be in the range of $75 per share, valuing the company at about $15.7 billion."
    Feb 20, 2013. 11:04 AM | Likes Like |Link to Comment
  • Nomura's Stuart Jeffrey's decision to start Apple (AAPL -1.9%) at Neutral has two parts: he thinks iPhone/iPad Mini supply constraints will limit Dec. quarter sales, and he thinks growth will decelerate from 2014 onwards. Developed markets growth is seen falling into the single digits, and while emerging markets are expected to be stronger, Jeffrey thinks Apple will need to sacrifice iPhone margins, as it goes after cost-sensitive customers receiving lower subsidies. Apple is now down 11% from its Sep. 21 high.  [View news story]
    Credit Suisse reaffirmed their outperform rating on shares of Apple (NASDAQ: AAPL) in a report issued on Tuesday. They currently have a $750.00 target price
    Oct 9, 2012. 11:37 AM | 1 Like Like |Link to Comment